These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338 [TBL] [Abstract][Full Text] [Related]
6. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018). Piérard D; Stone GG BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of tigecycline and comparators (2014-2016) among key WHO 'priority pathogens' and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study. Seifert H; Blondeau J; Dowzicky MJ Int J Antimicrob Agents; 2018 Oct; 52(4):474-484. PubMed ID: 30012439 [TBL] [Abstract][Full Text] [Related]
13. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Shortridge D; Kantro V; Castanheira M Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial. Zhang Z; Chen M; Yu Y; Pan S; Liu Y Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308 [TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study. Kiratisin P; Chongthaleong A; Tan TY; Lagamayo E; Roberts S; Garcia J; Davies T Int J Antimicrob Agents; 2012 Apr; 39(4):311-6. PubMed ID: 22386743 [TBL] [Abstract][Full Text] [Related]
17. Epidemiological, Physiological, and Molecular Characteristics of a Brazilian Collection of Carbapenem-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Dias VC; Resende JA; Bastos AN; De Andrade Bastos LQ; De Andrade Bastos VQ; Bastos RV; Diniz CG; Da Silva VL Microb Drug Resist; 2017 Oct; 23(7):852-863. PubMed ID: 28437232 [TBL] [Abstract][Full Text] [Related]
18. Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP). Mataseje LF; Bryce E; Roscoe D; Boyd DA; Embree J; Gravel D; Katz K; Kibsey P; Kuhn M; Mounchili A; Simor A; Taylor G; Thomas E; Turgeon N; Mulvey MR; J Antimicrob Chemother; 2012 Jun; 67(6):1359-67. PubMed ID: 22398651 [TBL] [Abstract][Full Text] [Related]
19. Nationwide surveillance of antimicrobial resistance among clinically important Gram-negative bacteria, with an emphasis on carbapenems and colistin: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2018. Lee YL; Lu MC; Shao PL; Lu PL; Chen YH; Cheng SH; Ko WC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Lee WS; Shi ZY; Chen YS; Wang FD; Tseng SH; Lin CN; Chen YH; Sheng WH; Lee CM; Liao MH; Hsueh PR Int J Antimicrob Agents; 2019 Sep; 54(3):318-328. PubMed ID: 31202925 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020. Karlowsky JA; Lob SH; Siddiqui F; Pavia J; DeRyke CA; Young K; Motyl MR; Sahm DF Braz J Infect Dis; 2023; 27(3):102775. PubMed ID: 37169345 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]